HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
ELAHERE safely and effectively. See full prescribing information for
ELAHERE.
ELAHERE
TM
(mirvetuximab soravtansine-gynx) injection, for
intravenous use
Initial U.S. Approval: 2022
WARNING: OCULAR TOXICITY
See full prescribing information for complete boxed warning.
• ELAHERE can cause severe ocular toxicities, including visual
impairment, keratopathy, dry eye, photophobia, eye pain, and
uveitis. (5.1, 6.1)
• Conduct an ophthalmic exam including visual acuity and slit
lamp exam prior to initiation of ELAHERE, every other cycle
for the first 8 cycles, and as clinically indicated. (2.3)
• Administer prophylactic artificial tears and ophthalmic topical
steroids. (2.3, 5.1)
• Withhold ELAHERE for ocular toxicities until improvement
and resume at the same or reduced dose. (2.4, 5.1)
• Discontinue ELAHERE for Grade 4 ocular toxicities. (2.4, 5.1)
-----------------------------INDICATIONS AND USAGE--------------------------
ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule
inhibitor conjugate indicated for the treatment of adult patients with FRα
positive, platinum-resistant epithelial ovarian, fallopian tube, or primary
peritoneal cancer, who have received one to three prior systemic treatment
regimens. Select patients for therapy based on an FDA-approved test. (1, 2.1)
This indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of clinical
benefit in a confirmatory trial. (1, 14)
------------------------DOSAGE AND ADMINISTRATION----------------------
• Administer ELAHERE as an intravenous infusion only after dilution in 5%
Dextrose Injection, USP. ELAHERE is incompatible with normal saline.
(2.5)
• The recommended dose of ELAHERE is 6 mg/kg adjusted ideal body
weight administered as an intravenous infusion every 3 weeks until disease
progression or unacceptable toxicity. (2.2)
• Premedicate with a corticosteroid, antihistamine, and antipyretic. (2.3)
• Premedicate with an antiemetic, ophthalmic topical steroids, and
lubricating eye drops. (2.3, 5.1)
• See full Prescribing Information for preparation and administration
instructions and dose modifications for adverse reactions. (2)
---------------------DOSAGE FORMS AND STRENGTHS----------------------
• Injection: 100 mg/20 mL (5 mg/mL) in a single-dose vial. (3)
-------------------------------CONTRAINDICATIONS------------------------------
• None. (4)
------------------------WARNINGS AND PRECAUTIONS-----------------------
• Pneumonitis: Withhold ELAHERE for persistent or recurrent Grade 2
pneumonitis and consider dose reduction. Permanently discontinue
ELAHERE for Grade 3 or 4 pneumonitis. (2.4, 5.2)
• Peripheral Neuropathy: Monitor patients for new or worsening peripheral
neuropathy. Withhold dosage, dose reduce, or permanently discontinue
ELAHERE based on the severity of peripheral neuropathy. (2.4, 5.3)
• Embryo-Fetal Toxicity: ELAHERE can cause fetal harm. Advise of the
potential risk to a fetus and to use effective contraception. (5.4, 8.1, 8.3)
-------------------------------ADVERSE REACTIONS------------------------------
The most common (≥20 %) adverse reactions, including laboratory
abnormalities, were vision impairment, fatigue, increased aspartate
aminotransferase, nausea, increased alanine aminotransferase, keratopathy,
abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea,
decreased albumin, constipation, increased alkaline phosphatase, dry eye,
decreased magnesium, decreased leukocytes, decreased neutrophils, and
decreased hemoglobin. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact ImmunoGen
at 1-833-486-4646 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
----------------------------DRUG INTERACTIONS---------------------------------
Strong CYP3A4 Inhibitors: Closely monitor for ELAHERE adverse reactions.
(7.1)
--------------------------USE IN SPECIFIC POPULATIONS---------------------
• Lactation: Advise not to breastfeed. (8.2)
• Moderate or severe hepatic impairment: Avoid use. (8.7)
See 17 for PATIENT COUNSELING INFORMATION and Medication
Guide.
Revised: 11/2022
FULL PRESCRIBING INFORMATION: CONTENTS*
BOXED WARNING
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Patient Selection
2.2 Recommended Dosage
2.3 Premedication and Prophylactic Regimen
2.4 Dosage Modifications
2.5 Instructions for Preparation and Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Ocular Disorders
5.2 Pneumonitis
5.3 Peripheral Neuropathy
5.4 Embryo-Fetal Toxicity
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
7 DRUG INTERACTIONS
7.1 Effects of Other Drugs on ELAHERE
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
12.6 Immunogenicity
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
15 REFERENCES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
* Sections or subsections omitted from the full prescribing
information are not listed.
Reference ID: 5077370